Artitis

1. tocilizumab (Actemra)

   Title: tocilizumab (Actemra)Category: MedicationsCreated: 9/13/2010 12:00:00 AMLast Editorial Review: 11/15/2019 12:00:00 AM (Source: MedicineNet Arthritis General)

   MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

2. penicillamine (Cuprimine, Depen)

   Title: penicillamine (Cuprimine, Depen)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 11/14/2019 12:00:00 AM (Source: MedicineNet Arthritis General)

3. ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis

   Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis (Source: HSMN NewsFeed)

4. ACR: Age at Psoriasis Onset Sets Course for Psoriatic Arthritis

   TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,... (Source: Drugs.com - Pharma News)

5. TREMFYA ® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies

   Findings from the DISCOVER-1 and DISCOVER-2 studies are presented, for the first time, at the 2019 American College of Rheumatology and Association of Rheumatology Professionals Annual MeetingThese are the first Phase 3 results evaluating p19-specific IL-23 inhibition in active psoriatic arthritis (Source: Johnson and Johnson)

6. Opioids Won't Help Arthritis Patients Long-Term: Study

   Title: Opioids Won't Help Arthritis Patients Long-Term: StudyCategory: Health NewsCreated: 11/9/2019 12:00:00 AMLast Editorial Review: 11/11/2019 12:00:00 AM (Source: MedicineNet Arthritis General)

   MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.

7. Fluorescence Optical Imaging for RA Treatment Monitoring Fluorescence Optical Imaging for RA Treatment Monitoring

   Could fluorescence optical imaging play a role in assessing treatment response in rheumatoid arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)

8. Penn uncovers dose of medication more likely to put patients with pemphigus into remission

   (University of Pennsylvania School of Medicine) Researchers from Penn compare a lymphoma-dose regimen of rituximab to a rheumatoid arthritis regimen for the treatment of pemphigus. (Source: EurekAlert! - Medicine and Health)

9. Skip ultrasound for treatment decisions in rheumatoid arthritis

   In patients with early rheumatoid arthritis, using ultrasound to guide treatment...Read more on AuntMinnie.comRelated Reading: SNMMI: Technetium radiotracer tracks rheumatoid arthritis C-11-based PET tracer could benefit arthritis patients Novel PET tracer could help assess arthritis Ultrasound helps fine-tune management of arthritis (Source: AuntMinnie.com Headlines)

10. China's Bio-Thera Gets Approval for Humira Biosimilar China's Bio-Thera Gets Approval for Humira Biosimilar

    China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira (adalimumab), paving the way for the first such biosimilar to enter the world's second-largest drug market.Reuters Health Information (Source: Medscape Allergy Headlines)

11. Opioids Won't Help Arthritis Patients Long-Term: Study

    SATURDAY, Nov. 9, 2019 -- Opioid painkillers may temporarily ease the discomfort of arthritis, but they have no clear lasting benefit, a research review finds. In an analysis of 23 clinical trials, researchers found that, on average, opioid... (Source: Drugs.com - Daily MedNews)

    MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

12. Navidea signs immunotherapy deal with IMV

    Radiopharmaceutical developer Navidea Biopharmaceuticals has signed an agreement...Read more on AuntMinnie.comRelated Reading: Navidea highlights rheumatoid arthritis results Navidea teams up with UAB to win NIH grant Navidea posts Q2 revenue decreases Navidea readies public stock offering Navidea points to upcoming study on TB probe (Source: AuntMinnie.com Headlines)

13. Race, Poverty Not Tied to Knee Replacement Outcomes

    THURSDAY, Nov. 7, 2019 -- Race and poverty are not significantly tied to total knee replacement (TKR) failure or revision, according to a study published in the November issue of Arthritis Care& Research. Anne R. Bass, M.D., from the the... (Source: Drugs.com - Pharma News)

14. China's Bio-Thera gets approval for Humira biosimilar

    China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world's second-largest drug market. (Source: Reuters: Health)

15. A hand surgeon's advice about knuckle cracking: Mayo Clinic Radio Health Minute

    Real deal or wives' tale: Knuckle cracking can cause harm, including arthritis? In this Mayo Clinic Radio Health Minute, we hear from a hand surgeon and his answer may surprise you. To listen, click the link below. A hand surgeons advice about knuckle cracking (Source: News from Mayo Clinic)

16. Mayo Clinic Minute: Benefits and risks of corticosteroid shots

    Corticosteroid injections are used to relieve pain in joints due to arthritis and overuse injuries. A recent study suggests that frequent steroid use may affect cartilage health. Dr. Raul Rosario-Concepcion, a Mayo Clinic sports medicine specialist, explains the benefits and risks of these injections. Watch: The Mayo Clinic Minute https://youtu.be/tYwUHex9HSc Journalists: Broadcast-quality video pkg (0:59) is [...] (Source: News from Mayo Clinic)

    MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.

17. Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller

    Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx (secukinumab) can beat the world's best-selling drug Humira (adalimumab) in treating a type of arthritis.Reuters Health Information (Source: Medscape Orthopaedics Headlines)

18. Mayo Clinic Minute: Fighting arthritis with food

    Millions of Americans suffer from symptoms of arthritis that are often debilitating. The most common form is degenerative arthritis, also known as osteoarthritis, followed by inflammatory or rheumatoid arthritis.?Dr. John Davis III, a Mayo Clinic rheumatologist, says what you eat may help with some of the inflammation associated with arthritis. Watch: The Mayo Clinic Minute [...] (Source: News from Mayo Clinic)

19. Medical News Today: Can you prevent psoriatic arthritis?

    It is impossible to know who will develop psoriatic arthritis, though it usually affects people who already have psoriasis. Learn about whether people can prevent psoriatic arthritis here. (Source: Health News from Medical News Today)

20. New data show how ICER ’s value framework could prevent or delay access to treatments for Medicaid patients across the country

    Anew analysis from Xcenda applied the Institute for Clinical and Economic Review ’s (ICER) value assessments to state Medicaid programs inCalifornia,Massachusetts,Maryland,NevadaandNew York. The study found these one-size-fits-all value assessments could prevent or delay access to prescriptions to treat serious, complex conditions like multiple sclerosis (MS), rheumatoid arthritis (RA), non-small cell lung cancer (NSCLC) and psoriasis. (Source: The Catalyst)